Introduction
Oral squamous cell carcinoma (OSCC) is a malignant tumor found most often in the head and neck region (1, 2) . The presence or absence of lymph node metastasis and the mode of invasion influence the outcomes of OSCC patients. Current treatment regimens are guided by traditional clinicopathologic factors such as TNM stage, histological grade, and patient age. Despite efforts over the past two decades, treatment approaches such as surgery, radiotherapy, chemotherapy, or combinations of these have had little effect on the improvement in the survival rate (3); for example, a reported 5-year survival rate of OSCC patients was poor (approximately 56%) (2) . To improve the prognoses of OSCC patients, the mechanisms underlying this cancer's pathogenesis and progression must be identified.
Tumor angiogenesis and lymphangiogenesis play an essential role in the growth, invasion, and metastatic spread of solid neoplasms (4) . Various angiogenesis factors and the group of their related factors have significant effects on angiogenesis and lymphangiogenesis. Vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF), and basic fibroblast growth factor (bFGF) are the main factors involved in angiogenesis. The VEGF family members that have been identified include VEGF-A, -B, -C, -D, and -E, and the receptors VEGFR-1, -2, and -3. Among them, VEGF-A promotes tumor angiogenesis by strongly stimulating the growth of tumor vascular endothelial cells and chemotactic factor (5) , and it is reported that expression of VEGF-A is related to tumor progression or poor prognosis in several human malignancies, including breast cancer (6), lung cancer (7), gastric cancer (8) , pancreatic cancer (9) , and prostate cancer (10) . Overexpression of VEGF-A has been reported to be significantly associated with lymph node metastasis, histo-logical differentiation, recurrence, and poor prognosis in head and neck cancer (11) . In addition, VEGF-C has been identified as a potent inducer of the lymphangiogenesis of tumor and lymph node metastasis (2, 12, 13) . There are previous studies of the association between clinicopathological factors and the expressions of VEGF-A and VEGF-C in oral SCC, but the outcome is controversial. In this study, we evaluated the expressions of VEGF-A and VEGF-C in oral SCC and investigated their relationship to clinicopathological factors and prognosis.
Materials and methods

Tissue samples
The subjects were 61 patients with primary OSCC who underwent surgical resection at the Department of Oral and Maxillofacial Surgery at Kanazawa University Hospital between 1989 and 2007. The tumors' TNM categories were classified according to the Union for International Cancer Control (UICC) system. The grade of tumor differentiation was determined according to the criteria proposed by the World Health Organization. The mode of tumor invasion was assessed according to the classification by Yamamoto et al. (14) . Details of the patient and tumor characteristics are given in Table 1 .
Cell lines
Three human oral squamous cell carcinoma cell lines with different invasive activities were used: OSC-20, OSC-19 (lower invasive type), and HOC313 (higher invasive type). OSC-20 is a cell line derived a 58-year-old female with metastatic tongue cancer to the cervical lymph nodes (15) . OSC-19 was derived from a 61-year-old male with metastatic tongue cancer to the cervical lymph node (16) . HOC313 was derived from a 51-year-old female with metastatic squamous cell carcinoma (involving the mandibular gingival and oral floor) to the cervical lymph nodes (17) . In addition, the normal human dermal fibroblast line (NHDF) was used as control.
Immunohistochemical staining
Tissue specimens were fixed in 10% neutral buffered formalin and embedded in paraffin; then, 4-mm-thick sections were cut. Immunohistochemical detection of VEGF-A and VEGF-C was performed using an anti-VEGF-A rabbit polyclonal antibody at 1:200 dilution (LifeSpan BioScience, Seattle, WA, USA) and anti-VEGF-C rabbit polyclonal antibody at 1:100 dilution (Life Technologies, Carlsbad, CA, USA), respectively. Tissue sections were deparaffinized with xylene and rehydrated in graded alcohol. Endogenous peroxidase was blocked by treatment with 0.3% hydrogen peroxide in methanol for 30 min and incubated with the primary antibodies at 4°C overnight. Bound antibody was detected using the Envision system (Dako, Carpinteria, CA, USA). Diaminobenzidine (1 mg/ml) in the presence of 0.03% hydrogen peroxidase was used to visualize any bound peroxidase, and sections were counterstained with hematoxylin. The specificities of the staining were confirmed by using non-immune serum instead of the primary antibody as a negative control. The expressions of VEGF-A and VEGF-C were evaluated with immunohistochemically stained preparations using anti-VEGF-A antibody and anti-VEGF-C antibody. Immunohistochemical evaluation was carried out in accord with the report of Takanashi (18) . The staining intensity of tumor cells in the leading invasion front regions was classified into four groups (0: none, 1: mild, 2: moderate, 3: strong), and cases were considered positive if their staining intensity was 2 or 3.
Enzyme-linked immunosorbent assay
For enzyme-linked immunosorbent assay analysis of VEGF-A and VEGF-C, supernatant of cultured several human oral cancer cell lines (OSC-19, OSC-20 and HOC313) and human normal dermal fibroblast cell lines (NHDF) were used. The supernatant was collected from cultured each cell line for 24 h. The concentrations of VEGF-A and VEGF-C were determined using ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocols.
Statistical analysis JMP â 9 (SAS Institute Inc., Cary, NC, USA) was used for data analysis. The relationships between the expression of these proteins and clinicopathological parameters were examined by the chi-square test. We calculated the 5-year survival rates by the Kaplan-Meier method and compared them using the log-rank test. Factors found to be significant were then chosen for Cox's multivariate proportional hazard model in order to ascertain their prognostic values. The significance level was set at 5% for each analysis. The data of ELISA are presented as the mean values AESEM.
The differences between groups were tested for statistical significance using the two-tailed Mann-Whitney U test. P-values <0.05 were considered statistically significant.
Results
Expression of VEGF-A and VEGF-C in oral SCC VEGF-A and VEGF-C were detected in the cytoplasm of tumor cells (Figs 1 and 2 ). According to the criteria for VEGF immunohistochemical evaluation, 46 cases (75.4%) were positive for VEGF-A, and 24 cases (39.3%) were positive for VEGF-C.
Association between VEGF-A or VEGF-C expression and clinicopathological features Table 2 displays the correlations between VEGF-A and VEGF-C expression and the patients' clinicopathological factors. VEGF-A expression was significantly correlated with lymph node metastasis (P < 0.05) but was not correlated with tumor size, local recurrence, histological differentiation, or mode of invasion. VEGF-C expression was significantly correlated with lymph node metastasis and local recurrence (P < 0.05) but was not correlated with tumor size, histological differentiation, location, or mode of invasion.
Correlations between VEGF-A or VEGF-C expression and survival time Figure 3 shows the Kaplan-Meier survival curves of the VEGF-A-positive and VEGF-C-positive groups compared to their negative group counterparts. The 5-year survival rate was 57.6% for the VEGF-A-positive group and 72.7% for the VEGF-A-negative group (Fig. 3A) . The VEGF-Apositive group showed low survival rates, but there was no significant difference in survival compared with the negative group (Fig. 3A) . The 5-year survival rate was 41.2% for the VEGF-C-positive group and 81.2% for the VEGF-Cnegative group (Fig. 3B) . The VEGF-C-positive group showed significantly poorer prognoses compared to the VEGF-C-negative group ( According to the expression intensity of VEGF-A, the samples are differentiated as positive (A) and negative (C) groups. The specificities of the staining were confirmed by using non-immune serum instead of the primary antibody as a negative control (B, D and F). Scale bar, 100 lm.
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The expressions of VEGF-A and VEGF-C in OSCC Yanase et al Cox proportional hazards regression analysis of the predictive factors for prognosis We performed a Cox proportional hazards regression analysis to examine the significance of the predictive factors. A univariate analysis revealed that the expression of VEGF-C and the mode of invasion were significant prognostic indicators, but not VEGF-A. In addition, a multivariate analysis showed that VEGF-C expression and the mode of invasion were independent prognostic factors ( Table 3) . 
Discussion
VEGF-A is a key tumor-derived growth factor that promotes the switch to an angiogenic phenotype in many tumors and other tissues. Interestingly, our study shows that the expression of VEGF-A is correlated with lymph node metastasis. This is most likely because VEGF-A can bind to VEGFR-1 and VEGFR-2, but not to VEGFR-3, which is expressed in lymphatic endothelial cells. Several studies have shown that VEGF-A can induce lymphangiogenesis According to the expression intensity of VEGF-C, the samples are differentiated as positive (A) and negative (C) groups. The specificities of the staining were confirmed by using non-immune serum instead of the primary antibody as a negative control (B, D and F). Scale bar, 100 lm.
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The expressions of VEGF-A and VEGF-C in OSCC Yanase et al (19, 20) . Other groups have demonstrated that VEGF-A expression is associated with lymph node metastasis (11, 21, 22) . A recent study reported that the VEGFR-2 receptor is occasionally expressed on lymphatic endothelial cells (23) . Unlike VEGFR-2, the affinity of VEGFR-1 for its ligand, VEGF-A, is approximately one order of magnitude higher than that of VEGFR-2. However, the kinase activity of VEGFR-1 is lower than VEGFR-2 (about one-tenth that of VEGFR-2), so VEGF-A is thought to act mainly through the activation of VEGFR-2 (3, (23) (24) (25) . These data suggest that VEGF-A may have a direct stimulatory effect on lymphatic vessels in OSCC. VEGF-C expression has been detected in a variety of tumors (26) (27) (28) (29) . VEGF-C, which binds to VEGFR-3, is known to be a major factor in lymphangiogenesis (30, 31) . VEGF-C binds to VEGFR-3 on the surface of lymphatic endothelial cells, inducing the proliferation and growth of new lymphatic vessels and leading to tumor cell dissemination and lymph node metastasis (2, 11, 32) . VEGF-C expression is associated with lymphatic vessel density (31, 33, 34) and lymph node metastases (30, 31, 35) in oral cancer. Pentheroudakis et al. (36) also reported an association between local recurrence and VEGF-C expression in head and neck cancer. In this study, we show that VEGF-C expression is associated with lymph node metastasis in OSCC. We also observed an association between VEGF-C expression and local recurrence. The data in this study are consistent with previous reports. However, further studies are needed to understand the precise role of VEGF-C in local recurrence.
There was no significant difference in the 5-year survival rate between patients from the VEGF-A-positive group and the VEGF-A-negative group. In contrast, the survival rate of the VEGF-C-positive group was significantly decreased compared to the VEGF-C-negative group. The results of our analysis using a Cox proportional hazards model show that the mode of invasion and VEGF-C expression are independent prognostic factors. Our ELISA data show that VEGF-C expression is significantly higher in a highly invasive cell line (HOC313) than in cell lines with lower invasiveness . Highly invasive OSCC is closely related to the prognosis (14) . These results suggest that VEGF-C may affect OSCC prognosis. The clinicopathological factors currently used to predict metastasis and prognosis include TNM classification, degree of differentiation, and mode of invasion. We propose including a molecular biological factor for comprehensive diagnoses in the future. More complete diagnostic methods not only improve the accuracy of diagnosing metastases, but could also help determine the prognosis and facilitate decision- The VEGF-C-positive group showed significantly poorer prognoses compared to the VEGF-C-negative group (P = 0.029).
The expressions of VEGF-A and VEGF-C in OSCC Yanase et al making regarding the necessity of prophylactic neck dissection. Our results suggest that VEGF-C may be a predictive factor for OSCC outcome. Recently, new therapies have been developed to target VEGF-A. However, resistance to anti-angiogenic therapies limits the clinical benefit of these agents in cancer patients. The single-agent response rate to anti-angiogenic drugs such as bevacizumab (a monoclonal antibody to VEGF-A) is <10%, and even in patients who do respond, the duration of the response is typically <3 months (37) (38) (39) . Similar response rates are observed in head and neck squamous cell carcinomas (40) , for which bevacizumab is being evaluated in phase III clinical trials. Our results suggest that therapies targeting VEGF-C may be expected to play a major role in the treatment of bevacizumab-resistant OSCC in the future. VEGF-A, vascular endothelial growth factor-A; VEGF-C, vascular endothelial growth factor-C.
